Brainstorm EVP to give presentation at Cell & Gene MeetingBy The Science Advisory Board staff writers
October 8, 2021
Lindborg will discuss the expansion of Brainstorm's technology portfolio, which includes autologous and allogeneic product candidates covering multiple neurological diseases. The company completed a phase III trial of NurOwn in amyotrophic lateral sclerosis patients, according to the company.
The presentation will be available as an on-demand webinar that will be available beginning October 12. At the conclusion of the meeting, a copy of the presentation will also be available in the Investors and Media section of the BrainStorm website under Events and Presentations.